My last post described the role of immunosenescence in the process of aging, and touched on immunotherapy as a potential strategy to restore immune function. Immunotherapy is being applied in various contexts, including cancer, to reprogram the immune system and build resiliency. Unfortunately, only a fraction of patients demonstrate durable, robust response to immunotherapy interventions, and the reason as to why remains elusive. A recent article proposes that the state of the microbiome and related gastrointestinal health could be the central governor of immunotherapy success.
Recent research has noted a trend of elevated populations of particular bacterial taxa in those who respond favorably to immune checkpoint inhibitor therapy. Akkermansia muciniphila, Bifidobacterium, and Faecalibacterium prausnitzii are keystone strains that exhibit a broad range of benefits, including maintenance of gut barrier integrity, release of short-chain fatty acids, and support of immunosurveillance. Nevertheless, their relative prevalence fails to predict response to immunotherapy intervention. Substantial inter-individual variability exists in the makeup of the gut microbiome, with no single compositional profile conferring consistent health outcomes. The health of the gut microbiome is not solely related to a specific distribution of microbial species, but is determined by the conglomeration of overall bacterial composition and competency, epithelial barrier integrity, and mucosal inflammatory state.
Diet, disease type, the treatment approach, and microbiome sequencing methods all behave as modifying variables of microbiome signatures. Divergent study characteristics introduce irreproducible outcomes that prohibit inferring associations between microbial composition and therapeutic response. However, antibiotics administered near the time of immunotherapy repeatedly compromise patient response. Pathobionts are allowed to bloom when commensals are repressed and no longer able to outcompete pathobiont proliferation. Pathobionts have been shown to induce a downregulation of ileal checkpoint molecule MAdCAM-1 that subsequently enables translocation of immunosuppressive T cells into the tumor microenvironment.
Dysbiosis elicits impaired mucosal immunity, a porous endothelial lining, loss of immunosurveillance, and progressive inflammatory activity. Supplementation with beneficial species, or undergoing fecal microbiota transplantation, has historically served to reinstate therapeutic efficacy. In large part, restoration of gastrointestinal homeostasis is driven by commensals supplanting pathobionts and inhibiting their immunosuppressive tendencies. This demonstrated cause and effect of commensal reintroduction and gut health reestablishment suggests the likely presence of a broad trend in the microbial community as a whole. One that is facilitative of ecological stability, structural resiliency, and functional capability is pivotal to treatment responsiveness. Instead of a single or specific grouping of beneficial microbial taxa, it is the global health of the gastrointestinal tract that is most predictive of cancer therapy potency.
A eubiotic state maintains immunosurveillance and inflammatory tone, ameliorates antigen presentation, and enhances T and B cell response. A dysbiotic state, in contrast, overwhelms the immune system by provoking epithelial damage, microbial byproduct translocation, activation of microbe- and damage-associated molecular patterns (MAMPs and DAMPs), diminished short-chain fatty acid signaling, altered bile acid transformation and tryptophan metabolism, as well as neutrophilic inflammation. The resulting systemic, chronic inflammation cripples immune resiliency and stifles immune reinvigoration following immunotherapeutic interventions.
As opposed to evaluating for the presence of specific microbial species, predictive value may be improved by assessing patient global gastrointestinal health through markers such as microbial diversity and composition, fecal calprotectin, sST2, stool human DNA fractions, SCFA production, primary and secondary bile acid concentrations, the tryptophan metabolites indole-3-aldehyde and indole-3-propionic acid, and sMAdCAM-1. Additionally, measuring systemic inflammation via the neutrophil-to-lymphocyte ratio, C-reactive protein, as well as quinolinic acid and kynurenine, can be illustrative of overall inflammatory tone. The development of a gut health index may be more telling of gastrointestinal health and deterministic of immunotherapeutic response. Such detailed analysis will likely enable creation of more comprehensive, and likely more effective, treatment approaches.
Sokol H, Elkrief A, Routy B. A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy. Mol Ther. 2026;34(6):3165-3170. doi:10.1016/j.ymthe.2026.04.034